commd7 Gene Expression in ALL

NCT05592470 | Unknown

• 1 other identifier: commd7 gene expression in ALL
• Study Type: observational
• Target: 102
• Locations: 0 countries
• Sites: N/A

Brief Summary

• study the expression pattern of COMMD7 gene in acute lymphoblastic leukemia.
• investigate correlation between the expression level of COMMD7 gene with other diagnostic parameters and prognosis in ALL .

Conditions

ALL

Keywords

COMMD7 , ALL

Outcome Measures

Primary Outcomes (1)

• The expression pattern of COMMD7 gene in acute lymphoblastic leukemia

  Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) TO DETECT EXPRESSION pattern in ALL

  BASELINE

Secondary Outcomes (1)

• Correlation between the expression level of COMMD7 GENE with other diagnostic parameters and prognosis in ALL

  baseline

Study Arms (2)

PATEINTS

51 patients newly diagnosed with acute lymphoblastic leukemia

Diagnostic Test: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).

controls

51 normal persons

Diagnostic Test: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).

Interventions

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). DIAGNOSTIC_TEST

Reverse transcription-quantitative polymerase chain reaction on bone marrow aspirates to detect The expression pattern of COMMD7 gene in acute lymphoblastic leukemia

PATEINTS; controls

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The required sample size will be 102 subject (51 newly diagnosed patients with ALL and 51 controls )

You may qualify if:

• Patients newly diagnosed with acute lymphoblastic leukemia , male or female at any age.

You may not qualify if:

• history of anti-neoplastic therapy, such as chemotherapy or radiotherapy.
• Any other types of cancers.
• Any clinically systemic acute or chronic inflammatory disease/s within one months.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (7)

• Garza-Veloz I, Martinez-Fierro ML, Jaime-Perez JC, Carrillo-Sanchez K, Ramos-Del Hoyo MG, Lugo-Trampe A, Rojas-Martinez A, Gutierrez-Aguirre CH, Gonzalez-Llano O, Salazar-Riojas R, Hidalgo-Miranda A, Gomez-Almaguer D, Ortiz-Lopez R. Identification of differentially expressed genes associated with prognosis of B acute lymphoblastic leukemia. Dis Markers. 2015;2015:828145. doi: 10.1155/2015/828145. Epub 2015 Feb 24.

  PMID: 25802479 BACKGROUND

• Short NJ, Kantarjian H, Jabbour E. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia. 2021 Nov;35(11):3044-3058. doi: 10.1038/s41375-021-01277-3. Epub 2021 Jun 25.

  PMID: 34172894 BACKGROUND

• Bartuzi P, Hofker MH, van de Sluis B. Tuning NF-kappaB activity: a touch of COMMD proteins. Biochim Biophys Acta. 2013 Dec;1832(12):2315-21. doi: 10.1016/j.bbadis.2013.09.014. Epub 2013 Sep 29.

  PMID: 24080195 BACKGROUND

• Burstein E, Hoberg JE, Wilkinson AS, Rumble JM, Csomos RA, Komarck CM, Maine GN, Wilkinson JC, Mayo MW, Duckett CS. COMMD proteins, a novel family of structural and functional homologs of MURR1. J Biol Chem. 2005 Jun 10;280(23):22222-32. doi: 10.1074/jbc.M501928200. Epub 2005 Mar 30.

  PMID: 15799966 BACKGROUND

• You N, Li J, Gong Z, Huang X, Wang W, Wang L, Wu K, Zheng L. COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma. Mol Carcinog. 2017 Feb;56(2):607-624. doi: 10.1002/mc.22520. Epub 2016 Jul 8.

  PMID: 27350032 BACKGROUND

• You N, Li J, Huang X, Wu K, Tang Y, Wang L, Li H, Mi N, Zheng L. COMMD7 promotes hepatocellular carcinoma through regulating CXCL10. Biomed Pharmacother. 2017 Apr;88:653-657. doi: 10.1016/j.biopha.2017.01.046. Epub 2017 Jan 29.

  PMID: 28142122 BACKGROUND

• Li K, Chen L, Zhang H, Wang L, Sha K, Du X, Li D, Zheng Z, Pei R, Lu Y, Tong H. High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia. Aging (Albany NY). 2021 Apr 23;13(8):11988-12006. doi: 10.18632/aging.202901. Epub 2021 Apr 23.

  PMID: 33891561 BACKGROUND

Central Study Contacts

marwa saad mohamed, master

CONTACT

0201003860750; qmarwa_1989@yahoo.com

sohair mohamed ahmed, doctoral

CONTACT

01223163678; Sohairmohamed2013@gmail.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: AssuitU

Study Record Dates

• First Submitted: October 20, 2022
• First Posted: October 24, 2022
• Study Start: November 1, 2022
• Primary Completion: April 1, 2024
• Study Completion: November 1, 2024
• Last Updated: October 24, 2022

Record last verified: 2022-09